http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102026138-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2018-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102026138-B1 |
| titleOfInvention | Composition for Inhibition or Treatment of Keloids and Hypertrophic Scar Comprising CRIF1 Antagonist |
| abstract | The present invention relates to compositions that are effective in inhibiting or treating the formation of keloids and hypertrophic scars by inhibiting proliferation and neovascularization, cell migration and ECM production. More particularly, CRIF1 (CR6 interacting) Factor 1) relates to a pharmaceutical composition for inhibiting or treating keloid and hypertrophic scar formation comprising an inhibitor of gene expression or an inhibitor of activity of CRIF1 protein as an active ingredient. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20230019795-A |
| priorityDate | 2017-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 64.